[Skip to Navigation]
Original Investigation
February 3, 2021

Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients: Long-term Outcomes of a Randomized Clinical Trial

Author Affiliations
  • 1College of Medicine, University of Cincinnati, Cincinnati, Ohio
  • 2Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada
  • 3Centre for Health Evaluation and Outcome Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • 4Division of Nephrology, Tufts–New England Medical Center, Boston, Massachusetts
  • 5Providence Health Care Research Institute, Vancouver, British Columbia, Canada
  • 6United Network for Organ Sharing, Richmond, Virginia
  • 7Comprehensive Transplant Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
JAMA Surg. 2021;156(4):307-314. doi:10.1001/jamasurg.2020.6929
Key Points

Question  Do long-term kidney transplant outcomes differ in patients treated with and without maintenance corticosteroids?

Findings  In a randomized clinical trial that allocated 385 patients to maintenance immunosuppressive treatment with tacrolimus and mycophenolate mofetil with or without corticosteroids, there was no difference in kidney allograft survival between treatment groups during the median follow-up of 15.8 years after transplant.

Meaning  Corticosteroids may not be necessary as part of a calcineurin-based multiple drug immunosuppressive regimen in kidney transplant recipients.

Abstract

Importance  The complications of corticosteroids make the inclusion of these drugs in immunosuppressive protocols for kidney transplant patients undesirable. However, cessation of corticosteroids is associated with a higher risk of short-term rejection, and the long-term outcomes of patients withdrawn from corticosteroids remain uncertain.

Objective  To compare long-term kidney transplant outcomes of patients randomized to continue or withdraw corticosteroids.

Design, Setting, and Participants  This prospective multicenter randomized double-blind placebo-controlled trial was conducted between November 1999 and December 2002 with linkage to a mandatory national registry with validated outcome ascertainment until June 8, 2018. The study included 28 kidney transplant centers in the United States, including 386 low– to moderate–immune risk adult recipients of a living or deceased donor kidney transplant without delayed graft function or short-term rejection in the first week after transplant. Analyses were intention to treat. Analysis began September 2018 and ended June 2019.

Interventions  Patients were randomized to receive tacrolimus and mycophenolate mofetil with or without corticosteroids 7 days after transplant.

Main Outcomes and Measures  Kidney allograft failure from any cause including death and allograft failure censored for patient death defined by the requirement for long-term dialysis or repeat transplant.

Results  Of 385 patients, 191 were assigned to withdraw from corticosteroids (mean [SD] age, 46.5 [12.1] years), and 194 patients were assigned to continued corticosteroids (mean [SD] age, 46.3 [12.6] years). The median (interquartile range) follow-up time was 15.8 (12.0-16.3) years after transplant. The adjusted hazard ratios of allograft failure from any cause including death was 0.83 (95% CI, 0.62-1.10; P = .19) and for allograft failure censored for patient death was 0.78 (95% CI, 0.52-1.19; P = .25) and did not differ between the patients assigned to withdraw from corticosteroids vs assigned to continued corticosteroids. Results were consistent in a per-protocol analysis among 223 patients who continued the trial-assigned treatment of corticosteroid withdrawal (n = 114) or corticosteroids (n = 109) through at least 5 years after transplant. The outcomes of trial participants in either treatment group did not differ from similarly treated contemporary registry patients who met trial eligibility criteria and were treated with the same immunosuppressive drugs.

Conclusions and Relevance  Long-term corticosteroids may not be necessary as part of a calcineurin-based multiple drug immunosuppressive regimen in low– to moderate–immune risk kidney transplant recipients.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×